Anti-tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards

IF 20.1 1区 医学 Q1 ONCOLOGY
Ling Tang, Yuanyuan Song, Hong Zhang, Ruimin Hao, Xin Tong, Xing Ai, Jun Ma, Zhimin Yang
{"title":"Anti-tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards","authors":"Ling Tang,&nbsp;Yuanyuan Song,&nbsp;Hong Zhang,&nbsp;Ruimin Hao,&nbsp;Xin Tong,&nbsp;Xing Ai,&nbsp;Jun Ma,&nbsp;Zhimin Yang","doi":"10.1002/cac2.12630","DOIUrl":null,"url":null,"abstract":"<p>Over the past decade, the research and development (R&amp;D) of anti-tumor drugs in China has undergone a remarkable leap, maintaining a high level of motivation.</p><p>With respect to pharmaceutical R&amp;D paradigms in China, the domestic market was once dominated by generic drugs. A progressive transition towards the development of innovative pharmaceuticals is emerging, consequent to the reforms in drug evaluation and approval mechanisms and the promotion of novel drug development in China. The introduction of new drugs from other countries to China used to lag behind. Now a progressive approach is being taken towards synchronization in global R&amp;D. The emergence of new players in the pharmaceutical industry and the enhancement of corporate R&amp;D competencies have further facilitated the internationalization of China's drug R&amp;D endeavors. The rapid advancement in pharmaceutical R&amp;D has significantly enhanced China's drug regulatory capabilities. In August 2015, the State Council of the People's Republic of China promulgated the “<i>Opinions on Reforming the Approval Procedures for Drugs and Medical Devices</i>” marking the official commencement of reforms in the drug evaluation and approval system. The Chinese drug regulatory authorities are integrating resources and optimizing drug review processes through the development of a scientifically complete system of Good Review Practice.</p><p>Innovative drugs, including new drugs, improved new drugs (those improved formulations or dose forms with existing active ingredients), biosimilars, and domestic generic drugs with unimported original drugs, constitute essential assurances for patients in China and offer better accessibility of medications. To better understand the changes since the inception of the drug evaluation and approval reforms in 2015, we have collected data on new drug applications (NDAs) for the aforementioned types of drugs submitted to the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) in China, spanning from January 2010 to March 2024.</p><p>A total of 374 NDAs for anti-tumor drugs had been approved from January 1, 2010 to March 31, 2024, including 186 (49.7%) imported drugs and 188 (50.3%) domestic drugs. The domestic drugs included 139 (37.1%) innovative/improved new drugs, 31 (8.3%) generic drugs, and 18 (4.8%) biosimilars, respectively.</p><p>Before 2018, China's pharmaceutical market mainly relied on domestic generic drugs. However, since 2018, the number of drug authorizations granted to innovative drugs has been on the rise, with a notable increase in domestically developed innovative drugs (Figure 1). The emergence of an upward trend in domestically R&amp;D innovative drugs is due to better regulatory frameworks, faster review processes, and the introduction of technical standards. The Chinese government has implemented policies promoting anti-tumor drug R&amp;D, including priority review, conditional approval, and breakthrough treatment designation. From 2010 to 2015, the CDE approved 45 anti-tumor drugs with an average review time of 580 days. From 2016 to 2024, the average review time for 329 applications dropped to 280.2 days. These measures enhanced review efficiency and transparency, offered a more predictable environment for drug development, and boosted the industry's confidence and interest in R&amp;D.</p><p>The advent of these domestic drugs has addressed much of the unmet needs of Chinese patients, transformed tumor therapeutics profoundly, and achieved success in the international market, thereby providing additional treatment options for patients worldwide. Bruton's tyrosine kinase inhibitor Zanubrutinib (Brukinsa®), which was granted an accelerated approval by the United States (US) Food and Drug Administration (FDA) in 2019, was tested in a pivotal study—a single-arm trial (SAT) —conducted in Chinese patients after consultation with the CDE to reach consensus.</p><p>Since 2012, the CDE has issued 61 guidance to support anti-tumor drug R&amp;D and address the technical challenges. This has contributed to the improvement of anti-tumor drug review framework in China.</p><p>Since China started the reforms in the drug review and approval system in 2015, the number of approvals of new drugs has been on the rise, with a steady increase in the number of applications that are globally synchronized. These achievements have reduced the disparity between domestic and international clinical practices, allowing Chinese patients to receive advanced therapeutic drugs and making it easier for pharmaceutical companies to synchronize global R&amp;D strategies.</p><p>The accelerated R&amp;D and launch of new drugs will ultimately reshape the landscape of tumor therapies, bringing more and diverse treatment options to patients in China. Moving forward, China's drug regulatory authorities are committed to advancing regulatory innovation for anti-tumor drugs to align with the evolving clinical treatment needs and drug R&amp;D demands. We will introduce and integrate advanced international evaluation methods to refine the drug approval process. Regulatory innovation will prioritize the drugs targeting rare and pediatric tumors. We aim to enhance R&amp;D efficiency and facilitate effective treatments through policy support. Additionally, we will promote the convergence of R&amp;D and clinical application of anti-tumor drugs to advance China's anti-tumor drug industry. China's drug regulatory authorities will remain committed to offering a greater number of high-quality, safe, and effective therapeutic drugs for cancer patients.</p><p><i>Research concept and design</i>: Jun Ma and Zhimin Yang. <i>Collection and/or assembly of data and policy</i>: Ling Tang, Yuanyuan Song. <i>Analysis and interpretation of data and policy</i>: Ling Tang, Yuanyuan Song, Hong Zhang, Ruimin Hao, Xin Tong, Xing Ai. <i>Article written</i>: Ling Tang. All authors approved the final manuscript.</p><p>The authors declare that they have no conflicts of interest.</p><p>Not applicable.</p><p>Not applicable.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"45 1","pages":"63-67"},"PeriodicalIF":20.1000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758239/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Communications","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cac2.12630","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Over the past decade, the research and development (R&D) of anti-tumor drugs in China has undergone a remarkable leap, maintaining a high level of motivation.

With respect to pharmaceutical R&D paradigms in China, the domestic market was once dominated by generic drugs. A progressive transition towards the development of innovative pharmaceuticals is emerging, consequent to the reforms in drug evaluation and approval mechanisms and the promotion of novel drug development in China. The introduction of new drugs from other countries to China used to lag behind. Now a progressive approach is being taken towards synchronization in global R&D. The emergence of new players in the pharmaceutical industry and the enhancement of corporate R&D competencies have further facilitated the internationalization of China's drug R&D endeavors. The rapid advancement in pharmaceutical R&D has significantly enhanced China's drug regulatory capabilities. In August 2015, the State Council of the People's Republic of China promulgated the “Opinions on Reforming the Approval Procedures for Drugs and Medical Devices” marking the official commencement of reforms in the drug evaluation and approval system. The Chinese drug regulatory authorities are integrating resources and optimizing drug review processes through the development of a scientifically complete system of Good Review Practice.

Innovative drugs, including new drugs, improved new drugs (those improved formulations or dose forms with existing active ingredients), biosimilars, and domestic generic drugs with unimported original drugs, constitute essential assurances for patients in China and offer better accessibility of medications. To better understand the changes since the inception of the drug evaluation and approval reforms in 2015, we have collected data on new drug applications (NDAs) for the aforementioned types of drugs submitted to the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) in China, spanning from January 2010 to March 2024.

A total of 374 NDAs for anti-tumor drugs had been approved from January 1, 2010 to March 31, 2024, including 186 (49.7%) imported drugs and 188 (50.3%) domestic drugs. The domestic drugs included 139 (37.1%) innovative/improved new drugs, 31 (8.3%) generic drugs, and 18 (4.8%) biosimilars, respectively.

Before 2018, China's pharmaceutical market mainly relied on domestic generic drugs. However, since 2018, the number of drug authorizations granted to innovative drugs has been on the rise, with a notable increase in domestically developed innovative drugs (Figure 1). The emergence of an upward trend in domestically R&D innovative drugs is due to better regulatory frameworks, faster review processes, and the introduction of technical standards. The Chinese government has implemented policies promoting anti-tumor drug R&D, including priority review, conditional approval, and breakthrough treatment designation. From 2010 to 2015, the CDE approved 45 anti-tumor drugs with an average review time of 580 days. From 2016 to 2024, the average review time for 329 applications dropped to 280.2 days. These measures enhanced review efficiency and transparency, offered a more predictable environment for drug development, and boosted the industry's confidence and interest in R&D.

The advent of these domestic drugs has addressed much of the unmet needs of Chinese patients, transformed tumor therapeutics profoundly, and achieved success in the international market, thereby providing additional treatment options for patients worldwide. Bruton's tyrosine kinase inhibitor Zanubrutinib (Brukinsa®), which was granted an accelerated approval by the United States (US) Food and Drug Administration (FDA) in 2019, was tested in a pivotal study—a single-arm trial (SAT) —conducted in Chinese patients after consultation with the CDE to reach consensus.

Since 2012, the CDE has issued 61 guidance to support anti-tumor drug R&D and address the technical challenges. This has contributed to the improvement of anti-tumor drug review framework in China.

Since China started the reforms in the drug review and approval system in 2015, the number of approvals of new drugs has been on the rise, with a steady increase in the number of applications that are globally synchronized. These achievements have reduced the disparity between domestic and international clinical practices, allowing Chinese patients to receive advanced therapeutic drugs and making it easier for pharmaceutical companies to synchronize global R&D strategies.

The accelerated R&D and launch of new drugs will ultimately reshape the landscape of tumor therapies, bringing more and diverse treatment options to patients in China. Moving forward, China's drug regulatory authorities are committed to advancing regulatory innovation for anti-tumor drugs to align with the evolving clinical treatment needs and drug R&D demands. We will introduce and integrate advanced international evaluation methods to refine the drug approval process. Regulatory innovation will prioritize the drugs targeting rare and pediatric tumors. We aim to enhance R&D efficiency and facilitate effective treatments through policy support. Additionally, we will promote the convergence of R&D and clinical application of anti-tumor drugs to advance China's anti-tumor drug industry. China's drug regulatory authorities will remain committed to offering a greater number of high-quality, safe, and effective therapeutic drugs for cancer patients.

Research concept and design: Jun Ma and Zhimin Yang. Collection and/or assembly of data and policy: Ling Tang, Yuanyuan Song. Analysis and interpretation of data and policy: Ling Tang, Yuanyuan Song, Hong Zhang, Ruimin Hao, Xin Tong, Xing Ai. Article written: Ling Tang. All authors approved the final manuscript.

The authors declare that they have no conflicts of interest.

Not applicable.

Not applicable.

Abstract Image

2010-2024年中国抗肿瘤药物监管:药品审评标准的演变与展望》。
在过去的十年里,中国抗肿瘤药物的研究和开发(R&amp;D)经历了一个显着的飞跃,保持了很高的动力。就中国的医药研发模式而言,国内市场曾一度以仿制药为主。随着中国药品审评和审批机制的改革以及对新药开发的促进,中国正在逐步向创新药物的发展过渡。中国从其他国家引进新药的工作过去一直滞后。现在正在采取一种渐进的办法来实现全球研发的同步。医药行业新参与者的出现和企业研发能力的提升,进一步促进了中国药物研发工作的国际化。医药研发的快速发展显著提高了中国的药品监管能力。2015年8月,中华人民共和国国务院发布《关于改革药品和医疗器械审批程序的意见》,标志着药品审评审批制度改革正式启动。中国药品监督管理部门正在整合资源,通过制定科学完整的良好审核规范体系来优化药品审核流程。创新药物,包括新药、改进的新药(使用现有有效成分的改进制剂或剂型)、生物仿制药和未进口原研药的国产仿制药,是对中国患者的基本保证,并提供了更好的药物可及性。为了更好地了解2015年药品审评和审批改革启动以来的变化,我们收集了2010年1月至2024年3月中国国家药品监督管理局(NMPA)药品审评中心(CDE)提交的上述类型药品的新药申请(nda)数据。2010年1月1日至2024年3月31日,共获批抗肿瘤新药申报374件,其中进口药品186件(49.7%),国产药品188件(50.3%)。其中,创新/改良新药139种(37.1%),仿制药31种(8.3%),生物仿制药18种(4.8%)。2018年之前,中国医药市场主要依靠国产仿制药。然而,自2018年以来,创新药获批数量呈上升趋势,其中国内研发的创新药增幅显著(图1)。国内研发创新药出现上升趋势,主要得益于监管框架更完善、审评流程更快以及技术标准的出台。中国政府实施了促进抗肿瘤药物研发的政策,包括优先审查、有条件批准和突破性治疗指定。2010 - 2015年,CDE共批准了45个抗肿瘤药物,平均审评时间为580天。从2016年到2024年,329件申请的平均审查时间下降到280.2天。这些措施提高了审评效率和透明度,为药物开发提供了一个更可预测的环境,并增强了行业对研发的信心和兴趣。这些国产药物的出现解决了中国患者的许多未满足的需求,深刻地改变了肿瘤治疗方法,并在国际市场上取得了成功,从而为全球患者提供了额外的治疗选择。Bruton的酪氨酸激酶抑制剂Zanubrutinib (Brukinsa®)于2019年获得美国食品和药物管理局(FDA)的加速批准,在与CDE协商达成共识后,在中国患者中进行了一项关键研究-单组试验(SAT)。自2012年以来,CDE已经发布了61项指导,以支持抗肿瘤药物的研发并应对技术挑战。这有助于中国抗肿瘤药物审评框架的完善。自2015年中国启动药品审评和审批制度改革以来,新药审批数量一直在上升,申请数量稳步增长,与全球同步。这些成就缩小了国内外临床实践的差距,使中国患者能够接受先进的治疗药物,并使制药公司更容易同步全球研发战略。新药研发和上市的加速最终将重塑肿瘤治疗的格局,为中国患者带来更多和多样化的治疗选择。展望未来,中国的药品监管部门将致力于推进抗肿瘤药物的监管创新,以适应不断变化的临床治疗需求和药物研发需求。 我们将引进和整合国际先进的评价方法,完善药品审批流程。监管创新将优先考虑针对罕见和儿童肿瘤的药物。我们的目标是通过政策支持,提高研发效率,促进有效的治疗。推动抗肿瘤药物研发与临床应用的融合,推动中国抗肿瘤药物产业的发展。中国药品监管部门将继续致力于为癌症患者提供更多高质量、安全、有效的治疗药物。研究概念与设计:马军、杨志敏。数据和政策的收集和/或组装:唐玲,宋媛媛。数据与政策分析与解读:唐玲,宋媛媛,张宏,郝瑞敏,童欣,艾兴。文章写:凌唐。所有作者都认可了最终稿。作者声明他们没有利益冲突。不适用。不适用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Communications
Cancer Communications Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
25.50
自引率
4.30%
发文量
153
审稿时长
4 weeks
期刊介绍: Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信